BioElectronics Corporation (OTC: BIEL), a developer of medical technology products, released an update from Chairman Richard Staelin, PhD, detailing sales growth, cost control achievements, and strategic progress. The company reported a small profit for calendar year 2025 following office relocations and staff reductions to align with operational needs. Initiatives to expand revenues include targeted advertising campaigns directed at medical professionals and healthcare providers to increase awareness of RecoveryRx among surgeons, pain specialists, and rehabilitation providers seeking non-opioid pain management options.
The company has also expanded consumer-focused social media advertising targeting Generation X consumers to promote drug-free solutions for chronic musculoskeletal pain. Outreach to physician-owned ambulatory surgical centers and orthopedic practices continues, with the goal of identifying a clinical trial partner for RecoveryRx. A postoperative clinical study could support future qualification for reimbursement under the federal NO PAIN Act initiative, representing a meaningful long-term opportunity for broader adoption of non-opioid pain management technologies in surgical settings.
Internationally, BioElectronics is working with legal counsel in Singapore and funders in China regarding arbitration proceedings involving a former distributor believed to have breached contractual obligations. The company remains committed to protecting its intellectual property and shareholder interests. Additionally, the strategic distribution and licensing relationship with Electrome Corporation has progressed, with initial conditions satisfied and manufacturing underway. Electrome is planning a commercial launch of BioElectronics' pulsed shortwave therapy products through its platform, providing another pathway to increase consumer awareness and access to FDA-cleared, drug-free pain therapy products.
Chairman Staelin emphasized that while the Electrome relationship is meaningful, it is part of a broader strategy including clinical market development, direct professional outreach, consumer education, international opportunities, and protection of contractual and intellectual property rights. Despite challenges faced by emerging medical technology companies, BioElectronics is encouraged by growing interest in non-drug pain management solutions and believes it is well positioned within the evolving electroceutical and non-opioid pain management markets. The company intends to continue advancing initiatives that support sustainable growth and build long-term value for shareholders.
